safety rosiglitazone treatment type num diabetes pubmed ncbi abstract background cardiovascular disease leading mortality adults type num diabetes thiazolidinediones including rosiglitazone approved treatment type num diabetes basis ability lower blood sugar surrogate markers cardiovascular disease objectives ascertain cardiovascular skeletal hematologic safety profile rosiglitazone methods synthesis evidence recent trials systematic reviews meta-analysis regulatory documents clinical trials registries manufacturers conclusion rosiglitazone increases risk heart failure myocardial infarction fractures women type num diabetes 
